Literature DB >> 11669603

Signalling events regulating lymphoid growth and survival.

P Brennan1.   

Abstract

Epstein-Barr virus (EBV) uses many different strategies to induce lymphocyte proliferation and survival. In the different states of EBV infection and latency, several genes play specific roles in the induction of cell growth and cell survival proteins. EBNA2A, EBNA-LP and EBNA3C all modulate early events in the G1 phase of the cell cycle. Furthermore, interleukin-6 and interleukin-10, which are induced following EBV infection, appear to be important for growth. They activate signalling pathways that have been shown to link directly to proliferation. Latent membrane protein 1 (LMP1) induces a number of anti-apoptotic proteins via NF- kappa B, and LMP2A also appears to contribute to lymphocyte survival. This paper describes some of the many cellular pathways modulated by EBV that interact with the signalling machinery and thus make lymphocytes survive and grow. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669603     DOI: 10.1006/scbi.2001.0408

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  3 in total

1.  Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A.

Authors:  Angharad M Shore; Paul C White; Rosaline C-Y Hui; Abdelkader Essafi; Eric W-F Lam; Martin Rowe; Paul Brennan
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  EPSTEIN -BARR VIRUS ASSOCIATION WITH MALIGNANT LYMPHOMA SUBGROUPS IN ZARIA, NIGERIA.

Authors:  Yawale Iliyasu; Leona W Ayers; Almustapha A Liman; Garba D Waziri; Sani M Shehu
Journal:  Niger J Surg Sci       Date:  2014

3.  Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.

Authors:  Ryan Incrocci; Molly McCormack; Michelle Swanson-Mungerson
Journal:  J Gen Virol       Date:  2013-01-09       Impact factor: 3.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.